Výsledky vyhledávání - "H. A. G. Lewis"

Evaluation of the effects of sodium–glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial

Autor: Anker, S.D. Butler, J. Filippatos, G.S. Jamal, W. Salsali, A. Schnee, J. Kimura, K. Zeller, C. George, J. Brueckmann, M. Zannad, F. Packer, M. Packer, M. Butler, J. Filippatos, G.S. Zannad, F. George, J. Brueckmann, M. Perrone, S. Nicholls, S. Janssens, S. Bocchi, E. Giannetti, N. Verma, S. Jian, Z. Gomez Mesa, J.E. Spinar, J. Böhm, M. Merkely, B. Chopra, V. Senni, M. Taddi, S. Tsutsui, H. Chuquiure, E. La Rocca, H.P.B. Ponikowski, P. Vinereanu, D. Sim, D. Choi, D.-J. Juanatey, J.R.G. Squire, I. Butler, J. Januzzi, J. Pina, I. Pocock, S.J. Carson, P. Doehner, W. Miller, A. Haas, M. Pehrson, S. Komajda, M. Anand, I. Teerlink, J. Rabinstein, A. Steiner, T. Kamel, H. Tsivgoulis, G. Lewis, J. Freston, J. Kaplowitz, N. Mann, J. Petrie, M. Bernstein, R. Cheung, A. Green, J. Januzzi, J. Kaul, S. Ping, C.L.S. Lip, G. Marx, N. McCullough, P. Mehta, C. Rosenstock, J. Sattar, N. Scirica, B. Tsutsui, H. Wanner, C. Welty, F.K. Parhofer, K.G. Clayton, T. Pedersen, T.R. Lees, K.R. Konstam, M.A. Greenberg, B. Palmer, M. the EMPEROR-Preserved Trial Committees Investigators

Background: The principal biological processes that characterize heart failure with a preserved ejection fraction (HFpEF) are systemic inflammation, epicardial adipose tissue accumulation, coronary microcirculatory rarefaction, myocardial fibrosis an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::c73b8bc19f1c5b0db1d943d289c92952
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3105582

Zobrazit plný text záznamu

Evaluation of the effect of sodium–glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial

Autor: Packer, M. Butler, J. Filippatos, G.S. Jamal, W. Salsali, A. Schnee, J. Kimura, K. Zeller, C. George, J. Brueckmann, M. Anker, S.D. Zannad, F. Butler, J. Zannad, F. George, J. Brueckmann, M. Perrone, S. Nicholls, S. Janssens, S. Bocchi, E. Giannetti, N. Verma, S. Jian, Z. Spinar, J. Seronde, M.-F. Böhm, M. Merkely, B. Chopra, V. Senni, M. Taddei, S. Tsutsui, H. Choi, D.-J. Chuquiure, E. La Rocca, H.P.B. Ponikowski, P. Juanatey, J.R.G. Squire, I. Butler, J. Januzzi, J. Pina, I. Pocock, S.J. Carson, P. Doehner, W. Miller, A. Haas, M. Pehrson, S. Komajda, M. Anand, I. Teerlink, J. Rabinstein, A. Steiner, T. Kamel, H. Tsivgoulis, G. Lewis, J. Freston, J. Kaplowitz, N. Mann, J. Petrie, M. Bernstein, R. Cheung, A. Green, J. Januzzi, J. Kaul, S. Ping, C.L.S. Lip, G. Marx, N. McCullough, P. Mehta, C. Rosenstock, J. Sattar, N. Scirica, B. Tsutsui, H. Wanner, C. Welty, F.K. Parhofer, K.G. Clayton, T. Pedersen, T.R. Lees, K.R. Konstam, M.A. Greenberg, B. Palmer, M. the EMPEROR-Reduced Trial Committees Investigators Executive Committee National Coordinators Consulting Statistician Clinical Events Committee Scientific Excellence Committee Data Monitoring Committee

Drugs that inhibit the sodium–glucose co-transporter 2 (SGLT2) have been shown to reduce the risk of hospitalizations for heart failure in patients with type 2 diabetes. In populations that largely did not have heart failure at the time of enrolmen

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::7c2522b6c13ffdaffd57f8e56b41746e
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3105612

Zobrazit plný text záznamu